Cipro (ciprofloxacin HCl)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved April 1996

Specific Treatments:


Therapeutic Areas

General Information

Cipro has been approved as treatment for acute, uncomplicated cystitis, caused by E.coli or Staphylococcus saprophyticus. Cystitis is one of the most common urinary tract infections (UTI) in females.

Cipro will be available in a blister pack that contains a full course of therapy, offering tablets to be taken twice a day for three days with or without food.

Cipro should not be administered concurrently with theophylline.

Side Effects

The most common side effects reported in the 100 mg CIPRO tablets clinical trials were headache, vaginal yeast infections, nausea, abdominal pain, dizziness, vaginitis and diarrhea. Rarely, however, were these side effects serious enough to cause women to discontinue therapy.

Additional Information

Annually, more than one million women suffer from cystitis, a bacterial infection of the urinary bladder, which causes a strong urge to urinate, frequency or difficulty in urinating, and abdominal/pelvic pain. Approximately one in five women will develop a UTI during her lifetime.

Cipro tablets have been marketed by Bayer in the United States since 1987 for the treatment of a wide variety of infectious diseases in adults such as urinary tract, lower respiratory tract, bone and joint, and skin structure infections.